Previous studies have documented how the use of a MAP2K2 inhibitor for BRAF-mutated melanoma triggers the PI3K/AKT pathway and leads to drug treatment resistance, although acquired MAP2K2 mutations have also been associated with the drug resistance [57,58]. The gene discussed is BRAF; the disease is melanoma.